11/14
11:31 am
xncr
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross [Yahoo! Finance]
Low
Report
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross [Yahoo! Finance]
11/12
05:39 am
xncr
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14% [Yahoo! Finance]
Low
Report
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14% [Yahoo! Finance]
11/8
11:17 am
xncr
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $34.00 price target on the stock, up previously from $32.00.
Low
Report
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $34.00 price target on the stock, up previously from $32.00.
11/7
01:41 pm
xncr
Xencor, Inc. (NASDAQ: XNCR) had its price target raised by analysts at JPMorgan Chase & Co. from $27.00 to $28.00. They now have an "overweight" rating on the stock.
Low
Report
Xencor, Inc. (NASDAQ: XNCR) had its price target raised by analysts at JPMorgan Chase & Co. from $27.00 to $28.00. They now have an "overweight" rating on the stock.
11/7
11:14 am
xncr
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $38.00 price target on the stock.
Low
Report
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $38.00 price target on the stock.
11/6
04:01 pm
xncr
Xencor Reports Third Quarter 2024 Financial Results
Low
Report
Xencor Reports Third Quarter 2024 Financial Results
11/4
07:00 am
xncr
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
Low
Report
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
11/1
11:55 am
xncr
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? [Yahoo! Finance]
Low
Report
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? [Yahoo! Finance]
10/10
08:21 am
xncr
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases [Yahoo! Finance]
Medium
Report
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases [Yahoo! Finance]
10/10
08:09 am
xncr
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
Medium
Report
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
10/4
08:01 am
xncr
Xencor Announces Upcoming Change to Board of Directors
Low
Report
Xencor Announces Upcoming Change to Board of Directors
9/26
11:04 am
xncr
Xencor, Inc. (NASDAQ: XNCR) had its price target raised by analysts at Royal Bank of Canada from $31.00 to $34.00. They now have an "outperform" rating on the stock.
Low
Report
Xencor, Inc. (NASDAQ: XNCR) had its price target raised by analysts at Royal Bank of Canada from $31.00 to $34.00. They now have an "outperform" rating on the stock.
9/12
04:01 pm
xncr
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Medium
Report
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
9/11
06:37 am
xncr
Xencor Announces Pricing of $175 Million Public Offering of Common Stock [Yahoo! Finance]
High
Report
Xencor Announces Pricing of $175 Million Public Offering of Common Stock [Yahoo! Finance]
9/11
06:31 am
xncr
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
High
Report
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
9/10
04:47 pm
xncr
Xencor announces public offering of common stock [Seeking Alpha]
High
Report
Xencor announces public offering of common stock [Seeking Alpha]
9/10
04:01 pm
xncr
Xencor Announces Proposed Public Offering of Common Stock
High
Report
Xencor Announces Proposed Public Offering of Common Stock
9/10
02:17 pm
xncr
Xencor Stock Gains 23% on Encouraging Pipeline Advancements [Yahoo! Finance]
Low
Report
Xencor Stock Gains 23% on Encouraging Pipeline Advancements [Yahoo! Finance]
9/9
06:17 pm
xncr
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.
Medium
Report
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.
9/9
04:28 pm
xncr
Xencor stock rallies 24% amid drug development updates [Seeking Alpha]
Medium
Report
Xencor stock rallies 24% amid drug development updates [Seeking Alpha]
9/9
07:57 am
xncr
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs [Yahoo! Finance]
High
Report
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs [Yahoo! Finance]
9/9
07:31 am
xncr
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
High
Report
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
9/6
08:12 am
xncr
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024 [Yahoo! Finance]
Medium
Report
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024 [Yahoo! Finance]
9/6
08:01 am
xncr
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
Medium
Report
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024